A tour de force provides novel insights into CD19-CAR T cell resistance mechanisms

Sworder et al.(1) developed an integrated simultaneous tumor and effector profiling (STEP) approach to study resistance mechanisms to CD19-CAR T cell therapy in large B-cell lymphomas. Their study provides novel biological insights and paves the way for future interventions.

Detalles Bibliográficos
Autores principales: Talleur, Aimee C., Gottschalk, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975327/
https://www.ncbi.nlm.nih.gov/pubmed/36812888
http://dx.doi.org/10.1016/j.xcrm.2023.100949
Descripción
Sumario:Sworder et al.(1) developed an integrated simultaneous tumor and effector profiling (STEP) approach to study resistance mechanisms to CD19-CAR T cell therapy in large B-cell lymphomas. Their study provides novel biological insights and paves the way for future interventions.

Ejemplares similares